<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9421441</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">35853345</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">9421441</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pii">S2213-1582(22)00177-2</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.nicl.2022.103112</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">103112</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Main approaches used for resting state fMRI analysis (rs-fMRI).</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Main approaches used for resting state fMRI analysis (rs-fMRI).</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>rs-fMRI Analysis</bold></th><th><bold>Description</bold></th><th><bold>Driven by</bold></th></tr></thead><tbody><tr><td>Seed-based approach</td><td>Correlation between a priori region (i.e., seeds) and the rest of the brain<break/></td><td>Hypothesis</td></tr><tr><td>Independent component analysis (ICA)</td><td>Identify components independent from each other</td><td>Data</td></tr><tr><td>Low frequency-fluctuation (ALFF)</td><td>Spontaneous fluctuation of specific regions</td><td>Hypothesis</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Main approaches used for resting state fMRI analysis (rs-fMRI).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>rs-fMRI Analysis</th><th>Description</th><th>Driven by</th></tr></thead><tbody><tr><td>Seed-based approach</td><td>Correlation between a priori region (i.e., seeds) and the rest of the brain</td><td>Hypothesis</td></tr><tr><td>Independent component analysis (ICA)</td><td>Identify components independent from each other</td><td>Data</td></tr><tr><td>Low frequency-fluctuation (ALFF)</td><td>Spontaneous fluctuation of specific regions</td><td>Hypothesis</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>t0010</table-id><table-label>Table 2</table-label><table-caption>Main networks investigated through rs-fMRI studies.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0010"><label>Table 2</label><caption><p>Main networks investigated through rs-fMRI studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold><italic>Networks</italic></bold></th><th><bold><italic>Anatomical areas</italic></bold></th><th><bold><italic>Functions</italic></bold></th></tr></thead><tbody><tr><td>Default Mode Network (DMN)</td><td><list list-type="simple" id="l0005"><list-item id="o0005"><label>●</label><p id="p0005">Posterior cingulate</p></list-item><list-item id="ce.list-item_lqc_ncg_f5b"><label>●</label><p id="p0010">Medial prefrontal cortex</p></list-item><list-item id="ce.list-item_bcg_ncg_f5b"><label>●</label><p id="p0015">Medial temporal cortex</p></list-item><list-item id="ce.list-item_zkj_ncg_f5b"><label>●</label><p id="p0020">Hippocampus</p></list-item><list-item id="ce.list-item_ob5_ncg_f5b"><label>●</label><p id="p0025">Lateral &amp; inferior parietal lobe</p></list-item><list-item id="ce.list-item_pjx_ncg_f5b"><label>●</label><p id="p0030">Medial frontal gyrus</p></list-item></list></td><td><list list-type="simple" id="l0010"><list-item id="o0010"><label>●</label><p id="p0035">Internal-oriented attention</p></list-item><list-item id="ce.list-item_nmb_4cg_f5b"><label>●</label><p id="p0040">Internal conversation</p></list-item><list-item id="ce.list-item_kt2_4cg_f5b"><label>●</label><p id="p0045">Introspection</p></list-item><list-item id="ce.list-item_yf3_4cg_f5b"><label>●</label><p id="p0050">Imagery</p></list-item></list></td></tr><tr><td>Dorsal Attentional Network (DAN)</td><td><list list-type="simple" id="l0015"><list-item id="o0015"><label>●</label><p id="p0055">Dorsolateral prefrontal cortex</p></list-item><list-item id="ce.list-item_wnx_4cg_f5b"><label>●</label><p id="p0060">Superior parietal cortex</p></list-item><list-item id="ce.list-item_xx1_pcg_f5b"><label>●</label><p id="p0065">Caudate</p></list-item></list></td><td><list list-type="simple" id="l0020"><list-item id="o0020"><label>●</label><p id="p0070">External-oriented attention</p></list-item><list-item id="ce.list-item_wds_4cg_f5b"><label>●</label><p id="p0075">Executive control</p></list-item></list></td></tr><tr><td>Ventral Attentional Network (VAN)</td><td><list list-type="simple" id="l0025"><list-item id="o0025"><label>●</label><p id="p0080">Basolateral amygdala</p></list-item><list-item id="ce.list-item_qcf_pcg_f5b"><label>●</label><p id="p0085">Ventral striatum</p></list-item><list-item id="ce.list-item_efj_pcg_f5b"><label>●</label><p id="p0090">Ventral-frontal cortex/lateral inferior prefrontal cortex</p></list-item><list-item id="ce.list-item_acm_pcg_f5b"><label>●</label><p id="p0095">Insula</p></list-item><list-item id="ce.list-item_rsp_pcg_f5b"><label>●</label><p id="p0100">Anterior cingulate</p></list-item><list-item id="ce.list-item_fbt_pcg_f5b"><label>●</label><p id="p0105">Temporo-parietal junction</p></list-item></list></td><td><list list-type="simple" id="l0030"><list-item id="o0030"><label>●</label><p id="p0110">Salient stimuli-oriented attention</p></list-item><list-item id="ce.list-item_k5x_pcg_f5b"><label>●</label><p id="p0115">Coordination with other networks</p></list-item></list></td></tr><tr><td>Visual Network (VN)</td><td><list list-type="simple" id="l0035"><list-item id="o0035"><label>●</label><p id="p0120">Occipital cortex</p></list-item><list-item id="ce.list-item_emc_qcg_f5b"><label>●</label><p id="p0125">Retina</p></list-item><list-item id="ce.list-item_xmf_qcg_f5b"><label>●</label><p id="p0130">Thalamic lateral geniculate nucleus</p></list-item></list></td><td><list list-type="simple" id="l0040"><list-item id="o0040"><label>●</label><p id="p0135">Processing visual stimuli</p></list-item></list></td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Main networks investigated through rs-fMRI studies.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Networks</th><th>Anatomical areas</th><th>Functions</th></tr></thead><tbody><tr><td>Default Mode Network (DMN)</td><td>●Posterior cingulate●Medial prefrontal cortex●Medial temporal cortex●Hippocampus●Lateral &amp; inferior parietal lobe●Medial frontal gyrus</td><td>●Internal-oriented attention●Internal conversation●Introspection●Imagery</td></tr><tr><td>Dorsal Attentional Network (DAN)</td><td>●Dorsolateral prefrontal cortex●Superior parietal cortex●Caudate</td><td>●External-oriented attention●Executive control</td></tr><tr><td>Ventral Attentional Network (VAN)</td><td>●Basolateral amygdala●Ventral striatum●Ventral-frontal cortex/lateral inferior prefrontal cortex●Insula●Anterior cingulate●Temporo-parietal junction</td><td>●Salient stimuli-oriented attention●Coordination with other networks</td></tr><tr><td>Visual Network (VN)</td><td>●Occipital cortex●Retina●Thalamic lateral geniculate nucleus</td><td>●Processing visual stimuli</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>t0015</table-id><table-label>Table 3</table-label><table-caption>Main characteristics of the ten rs-fMRI studies included in this systematic review. DLB: Lewy bodies dementia; PD: Parkinson’s disease; MSA: Multiple system atrophy; ePD: PD patients matched with MSA for disease duration; sPD: PD patients matched with MSA for severity of symptoms and equivalent treatment; H: hallucinations; HC: healthy controls; mH: minor hallucinations; VH: visual hallucinations; NPI: Neuropsychiatric Inventory; MDS-UPDRS: Movement Disorders Society-Unified Parkinson's Disease Rating Scale; PPRS: Parkinson Psychosis Rating Scale; SCOPA-PC: Scales for Outcomes in Parkinson Disease Psychiatric Complications; N.A.: not applicable.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0015"><label>Table 3</label><caption><p>Main characteristics of the ten rs-fMRI studies included in this systematic review. DLB: Lewy bodies dementia; PD: Parkinson’s disease; MSA: Multiple system atrophy; ePD: PD patients matched with MSA for disease duration; sPD: PD patients matched with MSA for severity of symptoms and equivalent treatment; H: hallucinations; HC: healthy controls; mH: minor hallucinations; VH: visual hallucinations; NPI: Neuropsychiatric Inventory; MDS-UPDRS: Movement Disorders Society-Unified Parkinson's Disease Rating Scale; PPRS: Parkinson Psychosis Rating Scale; SCOPA-PC: Scales for Outcomes in Parkinson Disease Psychiatric Complications; N.A.: not applicable.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Study</bold></th><th><bold>Sample</bold></th><th><bold>Disease Duration</bold></th><th><bold>Age</bold></th><th><bold>Hall. assessment</bold></th><th><bold>Hall. group: inclusion criteria</bold></th><th><bold>Exclusion criteria</bold></th><th><bold>Hall. treatment</bold></th></tr></thead><tbody><tr><td><xref rid="b0355" ref-type="bibr">Zorzi et al. (2021)</xref></td><td>10 DLB VH<break/><break/>13 DLB NH<break/><break/>13 HC</td><td>2.7 (1.25)<break/><break/>1.92 <break/>(1.11)</td><td>76.63 (7.35)<break/>74.44 <break/>(5.18)<break/>70.84 <break/>(10.85)<break/></td><td>NPI</td><td>N.A.</td><td>Severe cerebrovascular disease; primary psychiatric disorders; severe ocular diseases</td><td>N.A.<break/></td></tr><tr><td><xref rid="b0260" ref-type="bibr">Pezzoli et al. (2021a</xref>)</td><td>7 DLB VH<break/><break/>16 DLB NH</td><td>2.57 (1.4)<break/><break/>2.13 <break/>(1.31)</td><td>75.29 (5.09)<break/>73.5 <break/>(6.65)</td><td>NPI to assess presence, severity and frequency<break/></td><td>Recurrent, complex hallucination</td><td>Severe cerebrovascular disease; history of psychiatric disorders; severe eye pathology impairing visual acuity</td><td>N.A.</td></tr><tr><td><xref rid="b0320" ref-type="bibr">Walpola et al. (2020)</xref></td><td>18 PD H<break/><break/><break/>20 PD NH<break/><break/>20 HC</td><td>7.6 (5)<break/><break/>5.7 <break/>(3.2)</td><td>67.5 (6.7)<break/><break/>63.7<break/>(6.6)<break/>-</td><td>MDS-UPDRS (question 2)</td><td>Score ≥ 1, having VH (including minor (passage or illusions) or complex hallucinations<break/></td><td>N.A.</td><td>0/18 PD H</td></tr><tr><td><xref rid="b0030" ref-type="bibr">Bejr‐kasem et al. (2019)</xref></td><td>18 PD mH<break/><break/>14 PD NmH</td><td>5.2 (3.8)<break/><break/>4 <break/>(2)</td><td>70.4 (5.5)<break/>65.8 <break/>(6.9)</td><td>MDS-UPDRS</td><td>Minor hallucinations (i.e., sense of presence, passage h., visual illusions, pareidolias) weekly during the last month | stable h. 3 months before the study<break/></td><td>History of psychiatric disorders; cerebrovascular disease; conditions impairing mental status other than PD; factors impeding MRI scanning</td><td>0/18 PD mH</td></tr><tr><td><xref rid="b0180" ref-type="bibr">Hepp et al. (2017)</xref></td><td>15 PD VH<break/><break/>40 PD NVH<break/><break/>15 HC</td><td>12 (4)<break/><break/>11 <break/>(4)</td><td>69 (4)<break/><break/>67 <break/>(7)<break/><break/>67 <break/>(8)<break/><break/><break/><break/><break/></td><td>SCOPA-PC (1st item)</td><td>Based on the SCOPA-P score</td><td>Previous stereotactic surgery; white matter lesions and tumors at MRI</td><td>N.A.</td></tr><tr><td><xref rid="b0345" ref-type="bibr">Yao et al. (2016)</xref></td><td>12 PD VH<break/><break/>15 PD NH<break/><break/>14 HC</td><td>9 (3.5)<break/><break/>7.1 <break/>(5.1)</td><td>70<break/><break/><break/>66<break/><break/><break/>63</td><td>PPRS</td><td>Repetitive and complex VH of well-formed persons, animals or objects, lasting for at least 4 weeks, occurring once every 4 weeks<break/></td><td>Neurological disorders other than PD; major psychiatric disorders; depressive symptoms (MADRS ≥ 6); cognitive impairment with a MMSE &lt; 24; left-handedness</td><td>3/12 PD VH</td></tr><tr><td><xref rid="b0130" ref-type="bibr">Franciotti et al. (2015)</xref></td><td>15 sPD VH<break/><break/>15 sPD NH<break/><break/>15 HC NH<break/><break/>15 MSA<break/><break/>15 ePD NH</td><td>11.3 (4.3)<break/><break/>12 <break/>(4.5)</td><td>70 (6)<break/><break/>68 <break/>(11)<break/><break/>69 <break/>(6)<break/><break/>67 <break/>(5)<break/><break/>66 <break/>(9)</td><td>PPRS<break/><break/>NPI</td><td>Complex kinematic hallucinations based on the PPRS | patients with illusions (misperceptions) were excluded from any group<break/><break/></td><td>Minor hallucinations</td><td>0/15 sPD<break/>VH</td></tr><tr><td><xref rid="b0340" ref-type="bibr">Yao et al. (2015)</xref></td><td>12 PD VH<break/><break/>12 PD NH<break/><break/>14 HC NH</td><td>10 (3.5)<break/><break/>8.4 <break/>(5.1)</td><td>67.6 (7.4)<break/>63.4 <break/>(7.4)<break/>64.1 <break/>(4)</td><td>PPRS</td><td>Repetitive and complex VH of well-formed persons, animals or objects, lasting for at least 4 weeks, occurring once every 4 weeks<break/></td><td>Neurological disorders other than PD; major psychiatric disorders; depressive symptoms (MADRS &gt; 6); cognitive impairment with a MMSE &lt; 24; left-handedness</td><td>3/12 PD<break/>VH</td></tr><tr><td><xref rid="b0290" ref-type="bibr">Shine et al. (2015)</xref></td><td>10 PD VH<break/><break/>9 PD NH<break/><break/>10 HC NH</td><td>6.9 (4)<break/><break/>4.4 <break/>(3.3)</td><td>69.5 (8)<break/><break/>67.1 <break/>(7)<break/>63.5 <break/>(8)</td><td>MDS-UPDRS</td><td>BPP error score of 11 % used as cut-score<break/><break/><break/><break/></td><td>N.A.</td><td>N.A.</td></tr><tr><td><xref rid="b0335" ref-type="bibr">Yao et al. (2014)</xref></td><td>12 PD VH<break/><break/>12 PD NH<break/><break/>14 HC NH</td><td>10 (3.5)<break/><break/>8.4 <break/>(5.1)</td><td>67.6 (7.4)<break/>63.4 <break/>(7.4)<break/><break/>64.1<break/>(4)</td><td>PPRS</td><td>Repetitive and complex VH of well-formed persons, animals or objects, lasting for at least 4 weeks, occurring once every 4 weeks</td><td>Neurological disorders other than PD; major psychiatric disorders; depressive symptoms (MADRS &gt; 6); cognitive impairment with a MMSE &lt; 24; left-handedness</td><td>3/12 PD VH</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Main characteristics of the ten rs-fMRI studies included in this systematic review. DLB: Lewy bodies dementia; PD: Parkinson’s disease; MSA: Multiple system atrophy; ePD: PD patients matched with MSA for disease duration; sPD: PD patients matched with MSA for severity of symptoms and equivalent treatment; H: hallucinations; HC: healthy controls; mH: minor hallucinations; VH: visual hallucinations; NPI: Neuropsychiatric Inventory; MDS-UPDRS: Movement Disorders Society-Unified Parkinson's Disease Rating Scale; PPRS: Parkinson Psychosis Rating Scale; SCOPA-PC: Scales for Outcomes in Parkinson Disease Psychiatric Complications; N.A.: not applicable.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Sample</th><th>Disease Duration</th><th>Age</th><th>Hall. assessment</th><th>Hall. group: inclusion criteria</th><th>Exclusion criteria</th><th>Hall. treatment</th></tr></thead><tbody><tr><td>???</td><td>10 DLB VH13 DLB NH13 HC</td><td>2.7 (1.25)1.92 (1.11)</td><td>76.63 (7.35)74.44 (5.18)70.84 (10.85)</td><td>NPI</td><td>N.A.</td><td>Severe cerebrovascular disease; primary psychiatric disorders; severe ocular diseases</td><td>N.A.</td></tr><tr><td>???)</td><td>7 DLB VH16 DLB NH</td><td>2.57 (1.4)2.13 (1.31)</td><td>75.29 (5.09)73.5 (6.65)</td><td>NPI to assess presence, severity and frequency</td><td>Recurrent, complex hallucination</td><td>Severe cerebrovascular disease; history of psychiatric disorders; severe eye pathology impairing visual acuity</td><td>N.A.</td></tr><tr><td>???</td><td>18 PD H20 PD NH20 HC</td><td>7.6 (5)5.7 (3.2)</td><td>67.5 (6.7)63.7(6.6)-</td><td>MDS-UPDRS (question 2)</td><td>Score ≥ 1, having VH (including minor (passage or illusions) or complex hallucinations</td><td>N.A.</td><td>0/18 PD H</td></tr><tr><td>???</td><td>18 PD mH14 PD NmH</td><td>5.2 (3.8)4 (2)</td><td>70.4 (5.5)65.8 (6.9)</td><td>MDS-UPDRS</td><td>Minor hallucinations (i.e., sense of presence, passage h., visual illusions, pareidolias) weekly during the last month | stable h. 3 months before the study</td><td>History of psychiatric disorders; cerebrovascular disease; conditions impairing mental status other than PD; factors impeding MRI scanning</td><td>0/18 PD mH</td></tr><tr><td>???</td><td>15 PD VH40 PD NVH15 HC</td><td>12 (4)11 (4)</td><td>69 (4)67 (7)67 (8)</td><td>SCOPA-PC (1st item)</td><td>Based on the SCOPA-P score</td><td>Previous stereotactic surgery; white matter lesions and tumors at MRI</td><td>N.A.</td></tr><tr><td>???</td><td>12 PD VH15 PD NH14 HC</td><td>9 (3.5)7.1 (5.1)</td><td>706663</td><td>PPRS</td><td>Repetitive and complex VH of well-formed persons, animals or objects, lasting for at least 4 weeks, occurring once every 4 weeks</td><td>Neurological disorders other than PD; major psychiatric disorders; depressive symptoms (MADRS ≥ 6); cognitive impairment with a MMSE &lt; 24; left-handedness</td><td>3/12 PD VH</td></tr><tr><td>???</td><td>15 sPD VH15 sPD NH15 HC NH15 MSA15 ePD NH</td><td>11.3 (4.3)12 (4.5)</td><td>70 (6)68 (11)69 (6)67 (5)66 (9)</td><td>PPRSNPI</td><td>Complex kinematic hallucinations based on the PPRS | patients with illusions (misperceptions) were excluded from any group</td><td>Minor hallucinations</td><td>0/15 sPDVH</td></tr><tr><td>???</td><td>12 PD VH12 PD NH14 HC NH</td><td>10 (3.5)8.4 (5.1)</td><td>67.6 (7.4)63.4 (7.4)64.1 (4)</td><td>PPRS</td><td>Repetitive and complex VH of well-formed persons, animals or objects, lasting for at least 4 weeks, occurring once every 4 weeks</td><td>Neurological disorders other than PD; major psychiatric disorders; depressive symptoms (MADRS &gt; 6); cognitive impairment with a MMSE &lt; 24; left-handedness</td><td>3/12 PDVH</td></tr><tr><td>???</td><td>10 PD VH9 PD NH10 HC NH</td><td>6.9 (4)4.4 (3.3)</td><td>69.5 (8)67.1 (7)63.5 (8)</td><td>MDS-UPDRS</td><td>BPP error score of 11 % used as cut-score</td><td>N.A.</td><td>N.A.</td></tr><tr><td>???</td><td>12 PD VH12 PD NH14 HC NH</td><td>10 (3.5)8.4 (5.1)</td><td>67.6 (7.4)63.4 (7.4)64.1(4)</td><td>PPRS</td><td>Repetitive and complex VH of well-formed persons, animals or objects, lasting for at least 4 weeks, occurring once every 4 weeks</td><td>Neurological disorders other than PD; major psychiatric disorders; depressive symptoms (MADRS &gt; 6); cognitive impairment with a MMSE &lt; 24; left-handedness</td><td>3/12 PD VH</td></tr></tbody></table></div></transformed-table></extracted-table></extracted-tables-set>